Compare Lithium Americas Corp (LAC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs Revvity Inc — how do they compare? Lithium Americas Corp trades at $2.35 (market cap $850.38M), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 20× Lithium Americas Corp's market cap, and Revvity Inc pays a 0.18% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and Revvity Inc for 12 Days on average.
| LAC | RVTY | |
|---|---|---|
Market Cap | $850.38M | $16.98B |
Volume | 8,804,637 | 1,456,900 |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $157.36 |
52-Week Low | $2.35 | $82.26 |
Typical Hold Time | 27 Days | 12 Days |
Enterprise Value | $1.19B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.36, down 2.07% with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE at -9.56% and ROA at -3.99%, though it has beaten EPS estimates in recent quarters. Analyst consensus is mixed with 47% buy ratings and a $4.00 price target, representing 69% upside potential. Recent news highlights construction progress at Thacker Pass and a $175 million financing round to strengthen the balance sheet.
LAC presents a high-risk, high-reward opportunity as it transitions from development to execution phase. The stock trades below book value (P/B 0.6) but faces significant execution risks and negative cash flow from operations. Upside depends on successful lithium production ramp-up and favorable lithium pricing, while downside risks include project delays and commodity price volatility.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
